Yesterday, Jan. 21, 2016, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.00 to $2,727,667.28.

Highlighted Stocks Traded by Insiders:

Liberator Medical Holdings (LBMH) - FREE Research Report

Bard C R Inc /Nj/, who is 10% Owner at Liberator Medical Holdings, bought 1,000 shares at $0.01 on Jan. 21, 2016. Following this transaction, the 10% Owner owned 0 shares meaning that the stake was boosted by 100% with the 1,000-share transaction.

The shares most recently traded at $3.35, up $3.34, or 99.7% since the insider transaction. Historical insider transactions for Liberator Medical Holdings go as follows:

  • 4-Week # shares sold: 416,200
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 416,200
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 866,200

The average volume for Liberator Medical Holdings has been 363,800 shares per day over the past 30 days. Liberator Medical Holdings has a market cap of $180.5 million and is part of the health care sector and health services industry. Shares are up 0.3% year-to-date as of the close of trading on Wednesday.

Liberator Medical Holdings, Inc., together with its subsidiaries, operates as a mail order supplies company in the United States. The company distributes direct-to-consumer durable medical supplies primarily to seniors with chronic illnesses. The stock currently has a dividend yield of 2.39%. The company has a P/E ratio of 23.9. Currently, there are no analysts who rate Liberator Medical Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LBMH - FREE

TheStreet Quant Ratings rates Liberator Medical Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Liberator Medical Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ideal Power (IPWR) - FREE Research Report

Alexander Bill, who is Chief Technology Officer at Ideal Power, sold 8,000 shares at $5.36 on Jan. 21, 2016. Following this transaction, the Chief Technology Officer owned 439,996 shares meaning that the stake was reduced by 1.79% with the 8,000-share transaction.

The shares most recently traded at $6.00, up $0.64, or 10.68% since the insider transaction. Historical insider transactions for Ideal Power go as follows:

  • 4-Week # shares bought: 258,000
  • 4-Week # shares sold: 7,000
  • 12-Week # shares bought: 258,000
  • 12-Week # shares sold: 36,063
  • 24-Week # shares bought: 258,000
  • 24-Week # shares sold: 36,063

The average volume for Ideal Power has been 17,700 shares per day over the past 30 days. Ideal Power has a market cap of $50.7 million and is part of the industrial goods sector and industrial industry. Shares are down 29.88% year-to-date as of the close of trading on Thursday.

Ideal Power Inc. develops power conversion solutions with a focus on commercial and industrial grid storage, combined solar and storage, and microgrid applications. The company's principal products include power conversion systems, such as dual-port and multi-port battery converters. Currently, there are 4 analysts who rate Ideal Power a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPWR - FREE

TheStreet Quant Ratings rates Ideal Power as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and poor profit margins. Get the full Ideal Power Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Kronos Worldwide (KRO) - FREE Research Report

Schluter Klemens, who is COO - Global Operations at Kronos Worldwide, bought 10,000 shares at $4.37 on Jan. 21, 2016. Following this transaction, the COO - Global Operations owned 16,378 shares meaning that the stake was boosted by 156.79% with the 10,000-share transaction.

The shares most recently traded at $4.35, down $0.02, or 0.46% since the insider transaction. Historical insider transactions for Kronos Worldwide go as follows:

  • 4-Week # shares bought: 136,095
  • 12-Week # shares bought: 308,895
  • 24-Week # shares bought: 519,127

The average volume for Kronos Worldwide has been 386,500 shares per day over the past 30 days. Kronos Worldwide has a market cap of $490.2 million and is part of the basic materials sector and chemicals industry. Shares are down 20.57% year-to-date as of the close of trading on Thursday.

Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) worldwide. The stock currently has a dividend yield of 13.54%. The company has a P/E ratio of 1.1. Currently, there are no analysts who rate Kronos Worldwide a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KRO - FREE

TheStreet Quant Ratings rates Kronos Worldwide as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Kronos Worldwide Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.